Impact of obesity on treatment of chronic hepatitis C

被引：93

作者：

Charlton, Michael R.

Pockros, Paul J.

Harrison, Stephen A.

机构：

[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Coll Med, Rochester, MN 55905 USA

[2] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA USA

[3] Brooke Army Med Ctr, Div Gastroenterol & Hepatol, Ft Sam Houston, TX 78234 USA

来源：

HEPATOLOGY | 2006年 / 43卷 / 06期

关键词：

D O I：

10.1002/hep.21239

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Obesity and the metabolic syndrome have hepatic manifestations, including steatosis and progression of fibrosis. In individuals with chronic hepatitis C, obesity is associated with inflammation, insulin resistance, steatosis, progression of fibrosis, and nonresponse to treatment with interferon or peginterferon alpha and ribavirin. Patients with both hepatitis C and obesity-related nonalcoholic fatty liver disease are at greater risk for more advanced liver disease. We review the mechanisms by which obesity may be associated with decreased efficacy of interferon-based therapies in individuals with chronic hepatitis C and the therapeutic strategies that may increase the effectiveness of these therapies in obese individuals.

引用

页码：1177 / 1186

页数：10

共 130 条

[1] Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].

Adinolfi, LE ;

Gambardella, M ;

Andreana, A ;

Tripodi, MF ;

Utili, R ;

Ruggiero, G .

HEPATOLOGY, 2001, 33 (06) :1358-1364

[2] Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis [J].

Albano, E ;

Mottaran, E ;

Vidali, M ;

Reale, E ;

Saksena, S ;

Occhino, G ;

Burt, AD ;

Day, CP .

GUT, 2005, 54 (07) :987-993

[3]

Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO

[4]

2-S

[5] Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells [J].

Aleffi, S ;

Petrai, I ;

Bertolani, C ;

Parola, M ;

Colombatto, S ;

Novo, E ;

Vizzutti, F ;

Anania, FA ;

Milani, S ;

Rombouts, K ;

Laffi, G ;

Pinzani, M ;

Marra, F .

HEPATOLOGY, 2005, 42 (06) :1339-1348

[6]

[Anonymous], 2005, The IDF consensus worldwide definition of the metabolic syndrome

[7] Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].

Arita, Y ;

Kihara, S ;

Ouchi, N ;

Takahashi, M ;

Maeda, K ;

Miyagawa, J ;

Hotta, K ;

Shimomura, I ;

Nakamura, T ;

Miyaoka, K ;

Kuriyama, H ;

Nishida, M ;

Yamashita, S ;

Okubo, K ;

Matsubara, K ;

Muraguchi, M ;

Ohmoto, Y ;

Funahashi, T ;

Matsuzawa, Y .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83

[8] Steatosis in chronic hepatitis C: Why does it really matter? [J].

Asselah, T ;

Rubbia-Brandt, L ;

Marcellin, P ;

Negro, F .

GUT, 2006, 55 (01) :123-130

[9] Rational design of a potent, long-lasting form of interferon:: A 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C [J].

Bailon, P ;

Palleroni, A ;

Schaffer, CA ;

Spence, CL ;

Fung, WJ ;

Porter, JE ;

Ehrlich, GK ;

Pan, W ;

Xu, ZX ;

Modi, MW ;

Farid, A ;

Berthold, W .

BIOCONJUGATE CHEMISTRY, 2001, 12 (02) :195-202

[10]

Banerjee D, 2001, ANN ROY COLL SURG, V83, P268

← 1 2 3 4 5 6 7 8 9 10 →